Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | VCAN |
| Gene Name: | VCAN |
| Protein Full Name: | Versican core protein |
| Alias: | Chondroitin sulfate proteoglycan core 2; GHAP; Glial hyaluronate-binding; Large fibroblast proteoglycan; PG-M; Versica; VERSICAN; Versican proteoglycan |
| Mass (Da): | 372820 |
| Number AA: | 3396 |
| UniProt ID: | P13611 |
| Locus ID: | 1462 |
| COSMIC ID: | VCAN |
| Gene location on chromosome: | 5q14.2-q14.3 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19718 |
| Percent of cancer specimens with mutations: | 3.14 |
| General distribution of mutations: | Multi-site |
| Location of most mutations: | Broad distribution of mutation sites with several point mutations, but no complex, insertion or deletion mutants. |
| Normal role description: | VCAN is part of the aggrecan/versican proteoglycan family, and encodes a large chondroitin sulfate proteoglycan that is a major component of the extracellular matrix. It plays a role in cell adhesion, proliferation, proliferation, migration and angiogenesis, and in tissue morphogenesis and maintenance. Mutations in this gene are the cause of Wagner syndrome type 1. It is upregulated in numerous types of cancers, and probably functions as an oncoprotein by decreasing adhesiveness, and increasing cell motility and the rate of proliferation. |
| Commentary on involvement of protein in cancer: | 1/45 CNS samples and 1 pharyngeal/6 total UAT samples (mis-sense) were also mutated |